This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cooley, D. A. Search for Related Content PubMed PubMed Citation Articles by Cooley, D. A. Related Collections Other heart failure CV surgery: transplantation, ventricular assistance, cardiomyopathy

(Circulation. 2002;105:2808.)
© 2002 American Heart Association, Inc.

Editorial

Initial Clinical Experience With the Jarvik 2000 Implantable Axial-Flow Left Ventricular Assist System

Denton A. Cooley, MD

From the Texas Heart Institute, Houston.

Correspondence to Dr Denton A. Cooley, Texas Heart Institute, PO Box 20345, Houston, TX 77225-0345. E-mail dcooley@heart.thi.tmc.edu

Key Words: Editorials • transplantation • heart-assist device • heart failure

In this issue of Circulation, Frazier et al¹ report their initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular (LV) assist system. This report is gratifying to me for several reasons. First, I have been involved in the development of devices to replace or assist the failing heart since the 1960s.² I am also proud that the initial clinical work with this device was spearheaded by my colleague, Bud Frazier, who has worked tirelessly in this field since he was a medical student. Most important, however, is that this work gives hope to the 1 million patients with NYHA class III or IV heart failure who either die or suffer significant morbidity from their disease every year.³ New medications have helped delay the inevitable for some patients; however, a cure for chronic heart failure remains elusive. As heart failure worsens, medications become ineffective in treating the low contractility and pulmonary venous stasis that result from the increased dilatation of the heart. For patients with serious heart failure, the only hope is to unload the ventricle and augment the failing heart’s inadequate blood delivery. The Jarvik 2000 can do just that.

See p 2855

The Jarvik 2000 works differently than many other left ventricular assist devices (LVADs). Most of the LVADs currently in use were created as a result of an initiative by the National Heart, Lung, and Blood Institute (NHLBI) to develop a totally implantable long-term heart assist system. In 1977⁴ and 1980,⁵ requests for proposals (RFPs) . . . [Full Text of this Article]

This article has been cited by other articles:

				S. Haj-Yahia, E. J. Birks, P. Rogers, C. Bowles, M. Hipkins, R. George, M. Amrani, M. Petrou, J. Pepper, G. Dreyfus, et al. Midterm experience with the Jarvik 2000 axial flow left ventricular assist device J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 199 - 203. [Abstract] [Full Text] [PDF]

				B. Pieske Reverse remodeling in heart failure - fact or fiction? Eur. Heart J. Suppl., August 1, 2004; 6(suppl_D): D66 - D78. [Abstract] [Full Text] [PDF]

				J. J. DeRose Jr Invited commentary Ann. Thorac. Surg., January 1, 2003; 75(1): 183 - 183. [Full Text] [PDF]